Drugs with Dosage: POWDER;SUBCUTANEOUS
✉ Email this page to a colleague
Drugs with Dosage: POWDER;SUBCUTANEOUS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | Dosage |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biolinerx Ltd | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | POWDER;SUBCUTANEOUS | ||||
Biolinerx Ltd | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | POWDER;SUBCUTANEOUS | ||||
Teva Pharms Intl | SYNRIBO | omacetaxine mepesuccinate | POWDER;SUBCUTANEOUS | 203585-001 | Oct 26, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | POWDER;SUBCUTANEOUS | ||||
Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | POWDER;SUBCUTANEOUS | ||||
Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | POWDER;SUBCUTANEOUS | ||||
Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | POWDER;SUBCUTANEOUS | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration | >Dosage |